VO2Peak vs VO2Max, page-22

VO2Peak doesn’t need to become standard of care in oncology to make bisantrene a success, all that needs to happen is for oncologists to use bisantrene whenever they use an anthracycline. This will happen if bisantrene becomes SOC.

SOC is driven by clinical evidence changing the clinical guidelines. I doubt many oncologists would take the risk of using an anthracycline without bisantrene if it is in the guidelines - I am not sure what argument you would have in a medical negligence case if your patient develops heart failure and you chose to ignore the guidelines.

SOC is a huge pain when you are trying to introduce a new treatment, but it is a huge push once your treatment makes it onto the guidelines. A good recent example of this is in action is IPD.